PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10901311-5	2000	METHODS: We previously isolated a clonal cell line (MOS/ADR1) to study acquired resistance in osteosarcoma by exposure of parental murine osteosarcoma cells (MOS) to doxorubicin.	Doxorubicin	166-177	Moloney sarcoma oncogene	Mus musculus	52-55	
11299755-9	2001	These findings indicated that PEMFs reversed the DOX resistance of the MOS/ADR1 cells by inhibiting P-gp function.	Doxorubicin	49-52	Moloney sarcoma oncogene	Mus musculus	71-74	
10901311-7	2000	RESULTS: The MOS/ADR1 and MOS/IR1 cells were sevenfold and fivefold more resistant to doxorubicin than the parental murine osteosarcoma cells.	Doxorubicin	86-97	Moloney sarcoma oncogene	Mus musculus	13-16	
10901311-7	2000	RESULTS: The MOS/ADR1 and MOS/IR1 cells were sevenfold and fivefold more resistant to doxorubicin than the parental murine osteosarcoma cells.	Doxorubicin	86-97	Moloney sarcoma oncogene	Mus musculus	26-29	
10901311-13	2000	The addition of a P-glycoprotein antagonist, verapamil, or the depletion of cellular adenosine triphosphate resulted in a marked increase in the accumulation of doxorubicin in the MOS/ADR1 cells (p < 0.05) but not in the MOS/ IR1 cells.	Doxorubicin	161-172	Moloney sarcoma oncogene	Mus musculus	180-183	
10901311-13	2000	The addition of a P-glycoprotein antagonist, verapamil, or the depletion of cellular adenosine triphosphate resulted in a marked increase in the accumulation of doxorubicin in the MOS/ADR1 cells (p < 0.05) but not in the MOS/ IR1 cells.	Doxorubicin	161-172	Moloney sarcoma oncogene	Mus musculus	224-227	
10901311-5	2000	METHODS: We previously isolated a clonal cell line (MOS/ADR1) to study acquired resistance in osteosarcoma by exposure of parental murine osteosarcoma cells (MOS) to doxorubicin.	Doxorubicin	166-177	Moloney sarcoma oncogene	Mus musculus	158-161	
10901311-14	2000	The MOS/ADR1 cells were found to exhibit cross-resistance only to substrates for P-glycoprotein (such as doxorubicin, vincristine, and etoposide), whereas the MOS/IR1 cells were resistant to all of the drugs studied (including cisplatin and methotrexate).	Doxorubicin	105-116	Moloney sarcoma oncogene	Mus musculus	4-7	
8613443-5	1996	The MOS/ADR1 and MOS/ADR2 cells were sevenfold and eighteenfold more resistant to Adriamycin than the cells from the parent line.	Doxorubicin	82-92	Moloney sarcoma oncogene	Mus musculus	4-7	
8613443-5	1996	The MOS/ADR1 and MOS/ADR2 cells were sevenfold and eighteenfold more resistant to Adriamycin than the cells from the parent line.	Doxorubicin	82-92	Moloney sarcoma oncogene	Mus musculus	17-20